BFRI Stock Price, Biofrontera Inc. Quote, Chart

Market Summary

USD1.58+0.04

Market Closed

2.60%

BFRI Stock Price

View Fullscreen

BFRI RSI Chart

BFRI Valuation

Market Cap

7.8M

Price/Earnings (Trailing)

-0.39

Price/Sales (Trailing)

0.23

EV/EBITDA

-0.32

Price/Free Cashflow

-0.31

BFRI Price/Sales (Trailing)

BFRI Profitability

EBT Margin

-59.04%

Return on Equity

-420.01%

Return on Assets

-72.07%

Free Cashflow Yield

-317.76%

BFRI Fundamentals

BFRI Revenue

Revenue (TTM)

34.1M

Rev. Growth (Yr)

4.45%

Rev. Growth (Qtr)

19.1%

BFRI Earnings

Earnings (TTM)

-20.1M

Earnings Growth (Yr)

226.61%

Earnings Growth (Qtr)

155.6%

Breaking Down BFRI Revenue

Last 7 days

-21.4%

Last 30 days

-22.2%

Last 90 days

111.0%

Trailing 12 Months

-87.1%

How does BFRI drawdown profile look like?

BFRI Financial Health

Current Ratio

1.28

BFRI Investor Care

Shares Dilution (1Y)

13.68%

Diluted EPS (TTM)

-12.97

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	27.7M	29.0M	33.6M	34.1M
2022	29.1M	27.7M	27.7M	28.7M
2021	20.2M	21.5M	22.8M	24.1M
2020	0	0	22.5M	18.8M
2019	0	0	0	26.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biofrontera Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 18, 2023	monaco erica l.	acquired	-	-	76,336	chief executive officer
May 18, 2023	luebbert hermann	acquired	-	-	95,420	executive chairman
Aug 22, 2022	luebbert hermann	acquired	-	-	113,379	executive chairman
Jul 01, 2022	monaco erica l.	acquired	-	-	56,689	chief executive officer

Which funds bought or sold BFRI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	reduced	-2.41	1,057	1,147	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 25, 2024	Rosalind Advisors, Inc.	new	-	776,562	776,562	0.73%
Mar 11, 2024	VANGUARD GROUP INC	sold off	-100	-96,067	-	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-2.00	1.00	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	30.00	30.00	-%
Feb 14, 2024	CLEAR STREET LLC	unchanged	-	-	-	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 13, 2024	MORGAN STANLEY	new	-	554	554	-%

Are Funds Buying or Selling BFRI?

Are funds buying BFRI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BFRI

No. of Funds

Unveiling Biofrontera Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 20, 2024	lytton laurence w	9.99%	508,886	SC 13G
Mar 20, 2024	hirschman orin	9.9%	501,434	SC 13G
Mar 20, 2024	rosalind advisors, inc.	9.9%	504,261	SC 13G
Mar 20, 2024	rosalind advisors, inc.	9.9%	504,261	SC 13G
Mar 15, 2024	bigger capital, llc	4.9%	251,377	SC 13G
Feb 14, 2024	armistice capital, llc	9.99%	168,105	SC 13G
Nov 04, 2022	abshagen consulting gmbh	11.8%	3,148,042	SC 13G
Sep 19, 2022	deutsche balaton aktiengesellschaft	5.00%	1,177,676	SC 13D/A
Aug 25, 2022	deutsche balaton aktiengesellschaft	3.55%	835,734	SC 13D
Feb 10, 2022	biofrontera ag	46.8%	8e+06	SC 13G

Recent SEC filings of Biofrontera Inc.

View All Filings

Date Filed	Form Type	Document
May 07, 2024	SC 13G	Major Ownership Report
May 03, 2024	8-K	Current Report
May 03, 2024	S-1	Initial Public Offering
Apr 30, 2024	8-K	Current Report
Apr 30, 2024	DEFR14A	DEFR14A
Apr 25, 2024	8-K	Current Report
Apr 22, 2024	EFFECT	EFFECT
Apr 17, 2024	DEF 14A	DEF 14A
Apr 03, 2024	8-K/A	Current Report
Mar 26, 2024	8-K	Current Report

Peers (Alternatives to Biofrontera Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	358.5B	85.6B	-1.74%	-7.51%	9.32	4.19	5.68%	202.39%
MRK	328.0B	61.4B	2.34%	10.30%	142.26	5.34	6.11%	-82.30%
AMGN	164.9B	29.5B	14.19%	31.13%	43.82	5.58	12.76%	-52.47%
PFE	160.3B	57.8B	6.40%	-25.71%	127.84	2.77	76.51%	-86.81%
GILD	80.9B	27.4B	-6.51%	-17.64%	166.89	2.95	1.51%	-91.32%
TEVA	17.8B	16.0B	10.77%	72.86%	-36.05	1.11	7.23%	71.10%
MID-CAP
PRGO	4.2B	4.6B	-2.02%	-10.81%	-550.77	0.93	-0.06%	94.55%
ALKS	4.1B	1.7B	-7.02%	-22.02%	9.39	2.36	54.01%	364.56%
BHC	2.6B	9.0B	-27.55%	19.80%	-5.67	0.29	10.01%	-27.45%
AMPH	2.0B	644.4M	2.87%	15.89%	14.76	3.15	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-25.10%	-28.68%	-4.27	2.02	24.65%	80.36%
TXMD	23.3M	1.3M	-6.48%	-47.40%	-2.27	17.89	-98.14%	-109.18%
ACRX	17.5M	-	-11.21%	50.12%	-0.95	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	5.13%	-93.31%	-0.19	0.14	80.00%	43.08%
ACOR	968.8K	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Biofrontera Inc. News

Latest updates

Biofrontera Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Revenue	19.1%	10,595,000	8,896,000	5,848,000	8,733,000	10,144,000	4,322,000	4,457,000	9,751,000	9,167,500	4,334,000	5,855,000	4,744,000	3,998,000	3,252,000	-
Operating Expenses	7.0%	14,460,500	13,516,000	14,547,000	14,225,000	15,764,000	7,961,000	10,669,000	12,861,000	11,048,000	20,439,000	9,542,000	8,272,000	-	5,596,000	-
S&GA Expenses	5.6%	9,100,500	8,619,000	11,456,000	9,800,000	10,087,000	7,765,000	9,669,000	7,616,000	9,106,000	17,090,000	5,552,000	4,758,000	-	4,191,000	-
R&D Expenses	0%	33,000	33,000	11,000	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA Margin	24.0%	-0.60	-0.79	-0.78	-0.50	-0.02	-0.45	-0.93	-0.99	-1.57	-0.60	-0.64	-0.68	-0.73	-0.56	-0.48
Interest Expenses	-49.3%	-212,000	-142,000	-79,000	-35,000	-35,000	-89,000	-38,000	-33,000	-89,000	-86,000	-85,000	-84,000	-	-744,000	-
Income Taxes	-700.0%	-6,000	1,000	14,000	5,000	1,000	1,000	-	30,000	5,000	6,000	44,000	1,000	-	61,000	-
Earnings Before Taxes	155.5%	3,520,000	-6,341,000	-9,823,000	-7,473,000	-2,784,000	-2,565,000	-850,000	5,591,000	-14,500,500	-16,006,000	-3,617,000	-3,533,000	-	-2,924,000	-
EBT Margin	24.9%	-0.59	-0.79	-0.78	-0.49	-0.02	-0.44	-0.93	-0.98	-1.56	-0.48	-0.51	-0.54	-0.58	-0.49	-0.42
Net Income	155.6%	3,526,000	-6,342,000	-9,837,000	-7,478,000	-2,785,000	-2,566,000	-850,000	5,561,000	-14,505,500	-16,012,000	-3,661,000	-3,534,000	-	-2,985,000	-
Net Income Margin	24.9%	-0.59	-0.79	-0.78	-0.49	-0.02	-0.45	-0.93	-0.98	-1.56	-0.48	-0.51	-0.54	-0.58	-0.49	-0.42
Free Cashflow	-344.5%	-8,891,000	-2,000,000	-10,301,000	-3,701,000	-8,301,000	-5,914,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-18.1%	28.00	34.00	37.00	42.00	51.00	55.00	54.00	49.00	53.00	15.00	18.00	21.00	24.00	29.00
Current Assets	-22.1%	23.00	30.00	32.00	37.00	43.00	48.00	47.00	43.00	46.00	10.00	-	-	20.00	23.00
Cash Equivalents	-60.8%	1.00	3.00	4.00	14.00	17.00	28.00	32.00	22.00	25.00	2.00	-	-	8.00	7.00
Inventory	-32.1%	11.00	16.00	15.00	7.00	7.00	12.00	9.00	5.00	4.00	5.00	-	-	7.00	10.00
Net PPE	-13.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	0.00	1.00
Liabilities	-30.0%	23.00	33.00	30.00	25.00	27.00	32.00	36.00	32.00	42.00	33.00	28.00	23.00	18.00	59.00
Current Liabilities	-37.9%	18.00	29.00	25.00	20.00	21.00	17.00	15.00	12.00	14.00	11.00	-	-	4.00	12.00
Short Term Borrowings	-	4.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	361.8%	5.00	1.00	7.00	17.00	24.00	23.00	17.00	17.00	11.00	-	-	2.00	6.00	-
Retained Earnings	3.4%	-99.70	-103	-96.80	-87.00	-79.52	-76.73	-74.20	-73.30	-78.88	-64.40	-	-	-41.17	-30.18
Additional Paid-In Capital	0.2%	104	104	104	104	103	99.00	91.00	91.00	90.00	47.00	-	-	47.00	-
Shares Outstanding	11.0%	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	-
Float	-	-	-	14.00	-	-	-	35.00	37.00	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	-345.0%	-8,900	-2,000	-10,300	-3,700	-8,299	-5,913	113	-2,100	-20,990	-1,225	-1,100	-3,400	-	-	-
Share Based Compensation	10.1%	228	207	259	351	383	401	551	517	-	-	-	-	-	-	-
Cashflow From Investing	-80.9%	73.00	382	178	-14.00	-2,086	-3,034	-31.00	-5.00	-9.00	1.00	-	-	-	-	-
Cashflow From Financing	1036.0%	6,714	591	-	-	-	4,630	-	-	43,829	-121	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BFRI Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Products revenues, net	$ 34,005	$ 28,541
Revenues, related party	66	133
Total revenues, net	34,071	28,674
Operating expenses
Cost of revenues, related party	16,789	14,618
Cost of revenues, other	655	567
Selling, general and administrative	38,975	35,137
Selling, general and administrative, related party	152	733
Research and development	77
Change in fair value of contingent consideration	100	(3,800)
Total operating expenses	56,748	47,255
Loss from operations	(22,677)	(18,581)
Other income (expense)
Change in fair value of warrant liabilities	6,456	19,017
Warrant inducement expense	(1,045)	(2,629)
Excess of warrant fair value over offering proceeds	(2,272)
Change in fair value of investment, related party	(7,421)	1,747
Gain on legal settlement	7,385
Interest expense, net	(468)	(195)
Other income (expense), net	(75)	33
Total other income (expense)	2,560	17,973
Loss before income taxes	(20,117)	(608)
Income tax expense	14	32
Net loss	$ (20,131)	$ (640)
Loss per common share:
Basic	$ (13.02)	$ (0.61)
Diluted	$ (13.02)	$ (0.61)
Weighted-average common shares outstanding:
Basic	1,546,297	1,056,988
Diluted	1,546,297	1,056,988

BFRI Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,343	$ 17,208
Accounts receivable, net	5,162	3,748
Inventories, net	10,908	7,168
Prepaid expenses and other current assets	425	810
Total current assets	23,075	43,140
Property and equipment, net	134	204
Operating lease right-of-use assets	1,612	1,375
Intangible asset, net	2,629	3,032
Other assets	482	320
Total assets	27,932	50,884
Current liabilities:
Acquisition contract liabilities, net		6,942
Operating lease liabilities	691	498
Accrued expenses and other current liabilities	4,487	10,864
Short term debt	3,904
Total current liabilities	18,088	20,894
Long-term liabilities:
Acquisition contract liabilities, net		2,400
Warrant liabilities	4,210	2,843
Operating lease liabilities, non-current	804	848
Other liabilities	37	21
Total liabilities	23,139	27,006
Commitments and contingencies (see Note 23)
Stockholders’ equity:
Preferred Stock, $0.001 par value, 20,000,000 shares authorized, zero shares issued and outstanding as of December 31, 2023 and 2022
Common Stock, $0.001 par value, 15,000,000 shares authorized; 1,517,628 and 1,334,950 shares issued and outstanding as of December 31, 2023 and 2022	2	1
Additional paid-in capital	104,441	103,396
Accumulated deficit	(99,650)	(79,519)
Total stockholders’ equity	4,793	23,878
Total liabilities and stockholders’ equity	27,932	50,884
Related Party [Member]
Current assets:
Investment, related party	78	10,548
Other receivables, related party		3,658
Other assets, related party	5,159
Other receivables long term, related party		2,813
Current liabilities:
Accounts payable	5,698	1,312
Nonrelated Party [Member]
Current liabilities:
Accounts payable	$ 3,308	$ 1,278

About Biofrontera Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo. The company was founded in 1997 and is headquartered in Woburn, Massachusetts.

CEO	Dr. Hermann Luebbert Ph.D.
WEBSITE	biofrontera-us.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	81

Biofrontera Inc. Frequently Asked Questions

What is the ticker symbol for Biofrontera Inc.? What does BFRI stand for in stocks?

BFRI is the stock ticker symbol of Biofrontera Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biofrontera Inc. (BFRI)?

As of Wed May 08 2024, market cap of Biofrontera Inc. is 7.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BFRI stock?

You can check BFRI's fair value in chart for subscribers.

What is the fair value of BFRI stock?

You can check BFRI's fair value in chart for subscribers. The fair value of Biofrontera Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biofrontera Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BFRI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biofrontera Inc. a good stock to buy?

The fair value guage provides a quick view whether BFRI is over valued or under valued. Whether Biofrontera Inc. is cheap or expensive depends on the assumptions which impact Biofrontera Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BFRI.

What is Biofrontera Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, BFRI's PE ratio (Price to Earnings) is -0.39 and Price to Sales (PS) ratio is 0.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BFRI PE ratio will change depending on the future growth rate expectations of investors.